

NOVAVAX INC  
Form 8-K  
August 08, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported) August 3, 2012**

**NOVAVAX, INC.**

---

**(Exact name of Registrant as specified in its charter)**

Delaware  
(State or other jurisdiction of incorporation or  
organization)

0-26770  
(Commission File  
Number)

22-2816046  
(I.R.S. Employer Identification  
No.)

**9920 Belward Campus Drive**

20850

**Rockville, Maryland**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (240)  
268-2000

(Former name or former address, if changed since last report.)

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):**

- ..Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)**
- ..Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)**
- ..Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))**
- ..Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**

**Item 2.02 Results of Operations and Financial Condition.**

On August 3, 2012, Novavax, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter and six month period ended June 30, 2012 and conducted a previously announced, publicly available conference call to discuss those results as well as to provide an update on the status of the Company's business operations.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d)Exhibits

**Exhibits**

99.1	Press release issued by Novavax, Inc. on August 3, 2012
------	---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized

Novavax, Inc.  
(Registrant)

August 8, 2012 By: /s/ John A. Herrmann III  
Name: John A. Herrmann III  
Title: Vice President, General Counsel and Corporate Secretary